Frontiers in Oncology | Thoracic Oncology

Original Research

Published on 19 Apr 2021

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma

in Thoracic Oncology

Fangqiu Fu
Zhexu Wen
Zhendong Gao
Yue Zhao
Yuan Li
Yang Zhang
Haiquan Chen

Frontiers in Oncology

doi 10.3389/fonc.2021.622723

3,482 views
3 citations

Original Research

Published on 16 Apr 2021

Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis

in Thoracic Oncology

Yingji Chen
Longyu Jin
Zhibin Jiang
Suo Liu
Wei Feng

Frontiers in Oncology

doi 10.3389/fonc.2021.644426

5,877 views
25 citations

Original Research

Published on 16 Apr 2021

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

in Thoracic Oncology

Ya Chen
Zhengyu Yang
Yanan Wang
Minjuan Hu
Bo Zhang
Yanwei Zhang
Fangfei Qian
Wei Zhang
Baohui Han

Frontiers in Oncology

doi 10.3389/fonc.2021.671228

7,176 views
28 citations

Original Research

Published on 16 Apr 2021

Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates

in Thoracic Oncology

Jing Su
Lynn S. Huang
Ryan Barnard
Graham Parks
James Cappellari
Christina Bellinger
Travis Dotson
Lou Craddock
Bharat Prakash
Jonathan Hovda

Frontiers in Oncology

doi 10.3389/fonc.2021.584896

3,525 views
5 citations

Review

Published on 15 Apr 2021

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities

in Thoracic Oncology

Miriam Grazia Ferrara
Alessio Stefani
Michele Simbolo
Sara Pilotto
Maurizio Martini
Filippo Lococo
Emanuele Vita
Marco Chiappetta
Alessandra Cancellieri
Ettore D’Argento

Frontiers in Oncology

doi 10.3389/fonc.2021.650293

24,047 views
52 citations

Original Research

Published on 15 Apr 2021

The Expression of Three Negative Co-Stimulatory B7 Family Molecules in Small Cell Lung Cancer and Their Effect on Prognosis

in Thoracic Oncology

Meng-jun Qiu
Qin Xia
Yao-bing Chen
Xie-fan Fang
Qiu-ting Li
Li-sheng Zhu
Xin Jiang
Zhi-fan Xiong
Sheng-li Yang

Frontiers in Oncology

doi 10.3389/fonc.2021.600238

8,278 views
26 citations

Original Research

Published on 15 Apr 2021

Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer

in Thoracic Oncology

Amber M. Bates
Ryan J. Brown
Alexander A. Pieper
Luke M. Zangl
Ian Arthur
Peter M. Carlson
Trang Le
Gustavo A. Sosa
Paul A. Clark
Raghava N. Sriramaneni

Frontiers in Oncology

doi 10.3389/fonc.2021.645352

5,701 views
4 citations

Review

Published on 15 Apr 2021

Transition of Treatment for Ground Glass Opacity–Dominant Non-Small Cell Lung Cancer

in Thoracic Oncology

Yoshinori Handa
Yasuhiro Tsutani
Morihito Okada

Frontiers in Oncology

doi 10.3389/fonc.2021.655651

9,522 views
22 citations

Systematic Review

Published on 13 Apr 2021

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

in Thoracic Oncology

Qiang Wu
Wuxia Luo
Wen Li
Ting Wang
Lin Huang
Feng Xu

Frontiers in Oncology

doi 10.3389/fonc.2021.598265

10,263 views
42 citations

Original Research

Published on 12 Apr 2021

Prognostic Impact of Radiological Consolidation Tumor Ratio in Clinical Stage IA Pulmonary Ground Glass Opacities

in Thoracic Oncology

Junjie Xi
Jiacheng Yin
Jiaqi Liang
Cheng Zhan
Wei Jiang
Zongwu Lin
Songtao Xu
Qun Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.616149

7,853 views
43 citations

Original Research

Published on 12 Apr 2021

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

in Thoracic Oncology

Shetal A. Patel
David E. Gerber
Allison Deal
Kathe Douglas
Chad V. Pecot
Carrie Lee
Joan Schiller
Nirav Dhruva
Jared Weiss

Frontiers in Oncology

doi 10.3389/fonc.2021.666691

10,587 views
3 citations

Systematic Review

Published on 12 Apr 2021

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

in Thoracic Oncology

Rui-Lian Chen
Ling-Ling Sun
Yang Cao
Han-Rui Chen
Jing-Xu Zhou
Chu-Ying Gu
Ying Zhang
Si-Yu Wang
Wei Hou
Li-Zhu Lin

Frontiers in Oncology

doi 10.3389/fonc.2021.629394

8,386 views
28 citations

Original Research

Published on 09 Apr 2021

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

in Thoracic Oncology

Farastuk Bozorgmehr
Daniel Kazdal
Inn Chung
Martina Kirchner
Nikolaus Magios
Mark Kriegsmann
Michael Allgäuer
Laura V. Klotz
Thomas Muley
Rami A. El Shafie

Frontiers in Oncology

doi 10.3389/fonc.2021.640048

5,146 views
5 citations

Case Report

Published on 07 Apr 2021

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review

in Thoracic Oncology

Lingling Zhao
Zhen Wang
Haiwei Du
Songan Chen
Pingli Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.605853

3,998 views
9 citations

Original Research

Published on 07 Apr 2021

Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients

in Thoracic Oncology

Jie Yang
Hefei Li
Ben Li
Wei Li
Qiang Guo
Ling Hu
Zizheng Song
Bin Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.647598

8,273 views
12 citations

Original Research

Published on 31 Mar 2021

New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells

in Thoracic Oncology

Valentina Masciale
Federico Banchelli
Giulia Grisendi
Roberto D’Amico
Antonino Maiorana
Alessandro Stefani
Uliano Morandi
Massimo Dominici
Beatrice Aramini

Frontiers in Oncology

doi 10.3389/fonc.2021.613198

4,353 views
14 citations

Original Research

Published on 31 Mar 2021

Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma

in Thoracic Oncology

Ling Wang
Ayrianna Sparks-Wallace
Jared L. Casteel
Mary E. A. Howell
Shunbin Ning

Frontiers in Oncology

doi 10.3389/fonc.2021.632638

5,329 views
7 citations

Original Research

Published on 30 Mar 2021

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy

in Thoracic Oncology

Alex Friedlaender
Petros Tsantoulis
Mathieu Chevallier
Claudio De Vito
Alfredo Addeo

Frontiers in Oncology

doi 10.3389/fonc.2021.644472

12,420 views
28 citations

Original Research

Published on 26 Mar 2021

Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma

in Thoracic Oncology

Fei Shao
Xueli Bian
Juhong Wang
Daqian Xu
Wei Guo
Hongfei Jiang
Gaoxiang Zhao
Lei Zhu
Shuai Wang
Dongming Xing

Frontiers in Oncology

doi 10.3389/fonc.2021.561247

6,037 views
19 citations

Original Research

Published on 25 Mar 2021

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis

in Thoracic Oncology

Wenqian Li
Hanfei Guo
Lingyu Li
Jiuwei Cui

Frontiers in Oncology

doi 10.3389/fonc.2021.619376

5,645 views
5 citations

Original Research

Published on 25 Mar 2021

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs

in Thoracic Oncology

Li Ma
Haoyang Li
Dongpo Wang
Ying Hu
Mengjun Yu
Quan Zhang
Na Qin
Xinyong Zhang
Xi Li
Hui Zhang

Frontiers in Oncology

doi 10.3389/fonc.2021.643199

6,280 views
17 citations

Original Research

Published on 24 Mar 2021

Optimal Surgery Type and Adjuvant Therapy for T1N0M0 Lung Large Cell Neuroendocrine Carcinoma

in Thoracic Oncology

Kunwei Peng
Huijiao Cao
Yafei You
Wenzhuo He
Chang Jiang
Lei Wang
Yanan Jin
Liangping Xia

Frontiers in Oncology

doi 10.3389/fonc.2021.591823

3,773 views
9 citations

Original Research

Published on 23 Mar 2021

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

in Thoracic Oncology

Kenji Morimoto
Tadaaki Yamada
Chieko Takumi
Yuri Ogura
Takayuki Takeda
Keisuke Onoi
Yusuke Chihara
Ryusuke Taniguchi
Takahiro Yamada
Osamu Hiranuma

Frontiers in Oncology

doi 10.3389/fonc.2021.630136

6,633 views
34 citations

Original Research

Published on 22 Mar 2021

Prognostic Implication of the Expression Level of PECAM-1 in Non-small Cell Lung Cancer

in Thoracic Oncology

Shuhui Cao
Yue Wang
Jingwen Li
Xuxinyi Ling
Yao Zhang
Yan Zhou
Hua Zhong

Frontiers in Oncology

doi 10.3389/fonc.2021.587744

7,408 views
14 citations

1,976 articles

articles

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma

Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities

The Expression of Three Negative Co-Stimulatory B7 Family Molecules in Small Cell Lung Cancer and Their Effect on Prognosis

Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer

Transition of Treatment for Ground Glass Opacity–Dominant Non-Small Cell Lung Cancer

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Prognostic Impact of Radiological Consolidation Tumor Ratio in Clinical Stage IA Pulmonary Ground Glass Opacities

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review

Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients

New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells

Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy

Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs

Optimal Surgery Type and Adjuvant Therapy for T1N0M0 Lung Large Cell Neuroendocrine Carcinoma

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

Prognostic Implication of the Expression Level of PECAM-1 in Non-small Cell Lung Cancer